Articles & Issues

Alert me when new Articles in Press are available. Add Articles in Press Alert   Request Articles in Press Alert via email or RSS Feed   Request RSS feed of Articles in Press

9 Articles

  • 1
Article Title Author(s) Type (Status) Available Online
Heterogeneity among RIP-Tag2 insulinomas allows vascular endothelial growth factor-A independent tumor expansion as revealed by studies in Shb mutant mice: Implications for tumor angiogenesis

DOI: 10.1016/j.molonc.2012.01.006

Björn Åkerblom, Guangxiang Zang, Zhen W. Zhuang, Gabriela Calounova, Michael Simons, Michael Welsh et al. Full-length article
(In Press Uncorrected Proof)
06 February 2012
Inhibition of NEDD8-conjugation pathway by novel molecules: Potential approaches to anticancer therapy

DOI: 10.1016/j.molonc.2012.01.003

Tomoaki Tanaka, Tatsuya Nakatani, Tetsu Kamitani Review article
(In Press Uncorrected Proof)
27 January 2012
The toxin component of targeted anti-tumor toxins determines their efficacy increase by saponins

DOI: 10.1016/j.molonc.2012.01.004

Alexander Weng, Mayank Thakur, Figen Beceren-Braun, Diana Bachran, Christopher Bachran, Sebastian B. Riese, Kristina Jenett-Siems, Roger Gilabert-Oriol, Matthias F. Melzig, Hendrik Fuchs et al. Full-length article
(In Press Uncorrected Proof)
27 January 2012
Germline pharmacogenomics in oncology: Decoding the patient for targeting therapy

DOI: 10.1016/j.molonc.2012.01.005

Peter H. O'Donnell, Mark J. Ratain Review article
(In Press Uncorrected Proof)
25 January 2012
Structural and genic characterization of stable genomic regions in breast cancer: Relevance to chemotherapy

DOI: 10.1016/j.molonc.2012.01.001

Nicole I. Park, Peter K. Rogan, Heather E. Tarnowski, Joan H.M. Knoll Full-length article
(In Press Uncorrected Proof)
24 January 2012
Cancer immunotherapy

DOI: 10.1016/j.molonc.2012.01.002

Thomas F. Gajewski Review article
(In Press Corrected Proof)
13 January 2012
Adseverin: A novel cisplatin-resistant marker in the human bladder cancer cell line HT1376 identified by quantitative proteomic analysis

DOI: 10.1016/j.molonc.2011.12.002

Noriyoshi Miura, Nobuaki Takemori, Tadahiko Kikugawa, Nozomu Tanji, Shigeki Higashiyama, Masayoshi Yokoyama et al. Full-length article
(In Press Corrected Proof)
12 January 2012
The interaction of PKN3 with RhoC promotes malignant growth

DOI: 10.1016/j.molonc.2011.12.001

Keziban Unsal-Kacmaz, Shoba Ragunathan, Edward Rosfjord, Stephen Dann, Erik Upeslacis, Mary Grillo, Richard Hernandez, Fiona Mack, Anke Klippel et al. Full-length article
(In Press Corrected Proof)
03 January 2012
Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response

DOI: 10.1016/j.molonc.2011.11.010

Yu-Li Chen, Ming-Cheng Chang, Chia-Yen Huang, Ying-Cheng Chiang, Han-Wei Lin, Chi-An Chen, Chang-Yao Hsieh, Wen-Fang Cheng et al. Full-length article
(In Press Corrected Proof)
29 December 2011
  • 1


Note to users: The section "Articles in Press" contains peer reviewed and accepted articles to be published in this journal. When the final article is assigned to an issue of the journal, the "Article in Press" version will be removed from this section and will appear in the associated journal issue. Please be aware that "Articles in Press" do not have all bibliographic details available yet. There are three types of "Articles in Press":
  • Accepted Manuscripts: these are manuscripts that have been selected for publication. They have not been typeset and the text may change before final publication.
  • Uncorrected proofs: these are articles that are not yet finalized and that will be corrected by the authors. Therefore the text could change before final publication. Uncorrected proofs may be temporarily unavailable for production reasons.
  • Corrected proofs: these are articles containing the authors' corrections. The content of the article will usually remain unchanged, and possible further corrections are fairly minor. Typically the only difference with the finally published article is that specific issue and page numbers have not yet been assigned.